Peptide protocols are expensive. A mid-tier peptide clinic subscription — two compounds, quarterly consultations, compounded peptides — runs $400 to $800 per month. Gray-market alternatives are cheaper: $100 to $300 per month if you're sourcing your own. The question nobody asks before signing up: what is the expected value of that spend? Not "what would it be worth if it works?" but "what is it actually worth, multiplied by the probability it works at all?"

How to Think About Cost-Per-Outcome

Expected value analysis requires two inputs: the cost and the probability-weighted outcome. In pharmaceutical economics, this is formalized as cost-effectiveness analysis. For consumer purchases, it's simpler: before you pay for something, estimate both the probability it achieves the claimed result and the value of that result if achieved. Multiply them. Compare against the cost.

Most peptide marketing shows you one input (the value if it works) while suppressing the other (the probability it works). That's not cost-effectiveness analysis — it's advertising.

The Evidence-Adjusted Probability Problem

For any given peptide claim, the probability of the claimed outcome occurring is constrained by the evidence. Not entirely — real-world outcomes can exceed what trials predict — but evidence is the best prior you have.

The general probability framework for peptide claims based on evidence tier:

  • Human Phase III trial with positive results (e.g., semaglutide for weight loss): High confidence. The outcome probability in the real world is meaningful. The cost-per-outcome math is favorable when the outcome has high value.
  • Human Phase I or II trial only: Moderate confidence in safety. Low confidence in efficacy at the specific doses and indications being marketed. Probability of claimed outcome is substantially below the clinical trial success rate for Phase II drugs (roughly 50-60%).
  • Animal models only (most peptides): Very low confidence that animal-scale outcomes translate. The pharmaceutical industry's animal-to-Phase-II-success rate is approximately 10%. Apply this prior to your expected outcome probability.
  • Failed human trial (e.g., AOD-9604): Near-zero probability of the specific claimed outcome, since the best human trial didn't show it. AOD-9604's fat-loss claims are made against this backdrop.

A Real Cost-Per-Outcome Calculation for BPC-157

Let's price out a typical BPC-157 injury recovery protocol.

The claim: BPC-157 accelerates recovery from a musculoskeletal injury (tendon, ligament, or muscle strain) meaningfully faster than natural healing.

Cost (clinic-sourced): $300/month for the peptide, $200 initial consultation = ~$500 for a 6-week protocol. Gray-market equivalent: ~$80–120 total.

Evidence tier: Animal models only (no completed human efficacy trials). The claim draws entirely from rodent data with no validated human equivalent.

Probability of meaningful acceleration (animal-to-human base rate): ~10%, though the mechanism is plausible enough to argue for 20-30%. Call it 20% as an optimistic estimate.

Value of the outcome: Say you're recovering from a Grade 2 ankle sprain with a 6-week expected recovery timeline. If BPC-157 reduces this to 4 weeks, that's 2 weeks of faster recovery. Assign a value: if your time is worth $50/hour and you train 10 hours/week, 2 weeks of training time = $1,000 in value. More realistically, for most people, it's a meaningful but not enormous quality-of-life improvement.

Expected value (clinic-sourced): $1,000 outcome × 20% probability = $200 expected value, against $500 cost. Negative expected value unless your recovery time is worth a lot more to you, or you're more optimistic about the probability.

Expected value (gray-market): $1,000 × 20% = $200 expected value, against $100 cost. Positive expected value — but the quality risk (is the compound what it says?) significantly erodes the probability, and you're accepting unknown safety exposure.

This math is directionally correct even if the exact numbers are estimated. The outcome value has to be very high, or the probability has to be significantly better than the animal-to-human base rate, for the clinic-sourced cost to be justified on expected value alone.

The Scenarios Where Peptide Spend Is Defensible

None of this means peptide protocols are always poor value. The cases where the math shifts favorably:

High-stakes recovery where time has large economic value. A professional athlete whose next contract depends on returning from injury 4 weeks earlier has a very high dollar value assigned to recovery time. At that valuation, even a 10-20% probability of acceleration justifies meaningful cost. This is a real case where peptide expenditure can make economic sense even with weak evidence.

Compounds with better evidence tiers. GHK-Cu topical products for skin have several small but real human trials. The evidence probability is higher, making the cost-per-outcome more defensible for modest skincare goals — provided expectations match what the trials actually showed (modest improvement, not dramatic reversal).

Gray-market sourcing with verified quality and low-stakes application. If you source with confirmed independent COA, the cost is low, and the application is one where even a small probability of benefit has value to you — then the math can work. The ethics of uncontrolled human experimentation are a separate question.

The Hidden Costs Nobody Includes

Standard cost analyses miss several real costs of peptide protocols:

Time cost. Subcutaneous injection protocols require daily or twice-daily administration, reconstitution, sterile technique, and monitoring for adverse effects. If you value your time, this is real cost.

Psychological cost. Running a protocol with uncertain outcomes and uncertain safety introduces ongoing uncertainty that has real cognitive load. Some people find this energizing; many don't.

Opportunity cost. $400-800/month spent on unproven peptide protocols is not being spent on evidence-based interventions with established efficacy: physical therapy, sleep optimization, nutrition, or pharmaceutical interventions that have completed human trials.

Health risk cost. This is the one that's hardest to quantify and most frequently omitted. If long-term angiogenesis-promoting compound use has a 1-2% increased risk of accelerating pre-existing malignancy — a hypothetical risk with no established probability — what dollar value do you assign to that risk? Most people don't include this in the math at all.

The Bottom Line

Peptide protocols are only worth the cost if the expected value of the outcome exceeds the total cost including risk. For most people, at clinic-sourced prices, for most peptides, the math doesn't close — unless the outcome value is high (professional athlete) or the evidence tier is better than the typical animal-model-only profile.

That doesn't mean every protocol is a waste. It means the cost-effectiveness calculation is one you should run before signing up, not after. Start by scoring the specific claim you're being sold at PinPrick's claim scorer — it tells you exactly what evidence tier you're buying into before you spend anything.